Adocia announces expanded BioChaperone® product portfolio beyond diabetes

  • Following its successful application to diabetes treatments, BioChaperone® technology will now be deployed in a selected range of injectable therapeutics across numerous therapeutic areas
  • Initial programs added to the portfolio include a ready-to-inject version of teduglutide for the treatment of short bowel syndrome and a fixed dose combination of glucagon and exenatide for the treatment of obesity
  • Expansion of the portfolio creates new partnership opportunities

 

Adocia (Euronext Paris: FR0011184241- ADOC), the clinical biopharmaceutical company focused on developing innovative formulations of approved proteins for the treatment of diabetes and other metabolic diseases, today announced an update of its corporate strategy. The Company, which has built one of the most differentiated portfolio of injectable diabetes therapies, is expanding application of its proprietary BioChaperone® technology to new therapeutic areas.

Stilla Technologies, Yuzi Holdings and TusPark donate digital PCR Naica™ Systems to help fight coronavirus outbreak in China
Bayer, Meiogenix collaborate to accelerate agricultural innovation through the development of unique technologies
Other news
Median Technologies records its best quarterly performance and joins forces with biopharmaceutical companies in the fight against Covid-19.
HORAMA Signs Exclusive License Agreement with Leiden University Medical Center Targeting CRB1 Gene Mutations to Treat Inherited Retinal Dystrophies
Hungary and the Netherlands approve Lipiodol® Ultra Fluid for hysterosalpingography in women undergoing infertility workup
Alexis RIDEAU appointed Chief Executive Officer of DEINOVE with the ambition to strengthen the Company’s strategy for innovation and partnerships